Navigation Links
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
Date:6/22/2009

SEATTLE, June 22 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Stimuvax is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.

The Phase 3 trial, named STRIDE (STimulating immune Response In aDvanced brEast cancer), is anticipated to enroll more than 900 patients at approximately 180 sites in over 30 countries - including North America, Europe, Asia and Australia. Patients with estrogen receptor-positive and/or progesterone receptor-positive, non-resectable locally advanced, recurrent or metastatic breast cancer receiving hormonal therapy will be randomized to receive either Stimuvax or a placebo in a 2:1 ratio. The primary endpoint of STRIDE is progression-free survival. Overall survival, quality of life, tumor response and safety will also be assessed in this study.

"Advanced-stage breast cancer remains a devastating and challenging disease and we urgently need new treatment options," said Dr. Larry Shulman, Chief Medical Officer and Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute, Boston, Massachusetts, and Principal Investigator of STRIDE. "If the results from the Phase 3 STRIDE study prove positive, this could make a difference for patients with hormone receptor positive metastatic breast cancer."

"The initiation of the STRIDE study is an enormous step forward in clinical breast cancer research and represents our continued commitment to developing Stimuvax within a robust clinical trial program across several cancer types. We are very excited that Stimuvax will now be test
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
2. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Oncothyreon announces closing of $11.1 million registered direct financing
4. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
5. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
6. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Oncothyreon reports first quarter 2009 financial results
8. Oncothyreon regains compliance with NASDAQ listing requirements
9. Oncothyreon to present at Invest Northwest 2009
10. Oncothyreon reports full year and fourth quarter 2008 financial results
11. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Bed bugs have become so widespread ... Products, many turn to chemical-based pesticides for help to completely ... environmental risks those solutions present, the company advised the public ... instead. , According to My Cleaning Products, chemical-based pesticides ... to be. It shared that the pests have already developed ...
(Date:5/21/2013)... MN (PRWEB) May 21, 2013 Revolutionary ... patented automatic colony counter, announced today that they have ... products , the IncuCount, IntelliCount, InCount and ImpressCount. ... and sophistication are especially useful in food microbiology and ... given an updated look. A bright white enclosure ...
(Date:5/21/2013)... NANONEX CORPORATION, a pioneer and ... announced the successful delivery and installation of a ... to a major Japanese manufacturing company. ... advanced nanoimprint lithography tool that has the ability ... sizes and types. Based on Nanonex inventions and ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Inflamax ... of the ITN to design the study, which ... two key clinical models used in the study ... and Nasal Allergen Challenge (NAC) models. Although both ... numerous publications, to date no direct comparison between ...
Breaking Biology Technology:New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... , ,Your business card reads project manager. You ... to training, regularly participate in seminars and sleep with ... your desk is almost worn out; yellow sticky notes ... cost control section by heart! Youd rather have Gantt ...
... The Wisconsin Technology Council has published the first-ever ... highlights the states research base, technology-transfer process, company creation, ... that joins Chicago, Wisconsin and Minneapolis-St. Paul. , ... from Life Sciences: Wisconsin The Smart Choice ...
... routers at homes and businesses are still as secure as ... in an update about hackers who are targeting and exploiting ... , , Wardialing is an old hacking term used ... in a block (like 555-1200 to 555-1400) and trying to ...
Cached Biology Technology:Part 5 Project Performance Get on the path to continuous improvement 2Part 5 Project Performance Get on the path to continuous improvement 3Part 5 Project Performance Get on the path to continuous improvement 4Life Science: From company creation to growth: Doing business in Wisconsin 2Life Science: From company creation to growth: Doing business in Wisconsin 3Life Science: From company creation to growth: Doing business in Wisconsin 4Life Science: From company creation to growth: Doing business in Wisconsin 5Wardrivers now exploiting your wireless service with ease 2Wardrivers now exploiting your wireless service with ease 3Wardrivers now exploiting your wireless service with ease 4
(Date:5/21/2013)... Royal Philips Electronics (NYSE: PHG, AEX: PHIA) ... ultrasound with Philips, industry leading Live 3D TEE, now ... with available Live 3D TEE and ICE will be ... EuroPCR, official meeting for the European Association of Percutaneous ... launch in 2012, Philips CX50 xMATRIX has been the ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
(Date:5/20/2013)... colistin are also commonly resistant to antimicrobial substances ... study in mBio , the online open-access ... to colistin and host antimicrobials LL-37 and lysozyme, ... could mean that patients with life-threatening multi-drug resistant ... response. Colistin is a last-line drug for treating ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... New Applications of Titanium,s Core Technology in the ... 27 Titanium Group, Ltd,(OTC Bulletin Board: TTNUF), ... it has signed a contract with Hong Kong,Polytechnic ... pharmacy,system powered by Titanium,s Biometric Facial Recognition technology. ...
... Growing Demand for High-Performance Notebook Computers ... and Consumer Electronic Applications, ... of,America, Inc., a leading supplier of innovative computer products ... the launch of its MHZ2 BH series mobile hard ...
... ,On Stem Cell Therapy for Cardiovascular Diseases ... Cell-Based Therapeutic Approaches to Cardiovascular Diseases WHAT: ... to New York City from around the world ... Therapy for Cardiovascular Diseases. Dedicated to new advances ...
Cached Biology News:Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 2Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 3Fujitsu Announces Industry Highest Capacity 2.5 Inch SATA Hard Disk Drive at 320GB(1) 2Fujitsu Announces Industry Highest Capacity 2.5 Inch SATA Hard Disk Drive at 320GB(1) 3Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases 2Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases 3
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
...
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: